Bristol Myers Squibb's $14B Buyout Yields Breakthrough: KarXT Shows Year-Long Schizophrenia Relief
April 6, 2024
Bristol Myers Squibb acquired Karuna Therapeutics for $14 billion.
KarXT, a schizophrenia drug developed by Karuna, shows sustained efficacy over one year.
Over 75% of patients experienced a 'clinically meaningful' result from KarXT after one year.
Long-term data on KarXT was presented at the Schizophrenia International Research Society congress.
Summary based on 1 source
Get a daily email with more Medicine stories
Source
Endpoints News • Apr 6, 2024
Bristol Myers touts long-term efficacy of recently acquired Karuna drug